Authorization

Orphazyme announces confidential submission of a draft registration statement for a potential registered public offering in the United States

Orphazyme A/S
Company announcementA  A  A  A  A  A  A  A  A  A  A  A  A  A  A  A  A  A  A  A  A  A  A  A  A  A  A  A  A  A  A  A  A  A  A  A  A  A  A A 
No. 37/2020
Company Registration No. 32266355
Copenhagen, Denmark, July 1, 2020 a?? Orphazyme A/S (ORPHA.CO) (the a??Companya??), a late-stage biopharmaceutical company harnessing the amplification of the Heat-Shock Proteins in order to develop and commercialize novel therapeutics for the treatment of neurodegenerative orphan diseases, today announced that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission (a??SECa??) relating to a potential registered public offering of the Companya??s ordinary shares, in the form of American Depositary Shares (a??ADSsa??), in the United States. The draft registration statement is subject to ongoing review by the SEC, and the proposed listing of ADSs representing the Company's ordinary shares is subject to approval for listing on the Nasdaq Global Market. The Company's ordinary shares will continue to be admitted for trading on Nasdaq Copenhagen. Any potential offering is subject to market and other conditions, including board approval. A This company announcement does not constitute an offer to sell or the solicitation of an offer to buy any securities issued or to be issued by the Company. Any offers, solicitations or offers to buy, or any sales of securities issued or to be issued by the Company will be made in accordance with the registration requirements of the Securities Act of 1933, as amended (the a??Securities Acta??). This announcement is being issued in accordance with Rule 135 under the Securities Act.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Август 2022    »
ПнВтСрЧтПтСбВс
1234567
891011121314
15161718192021
22232425262728
293031